The Expression And Clinical Significance Of SLC40A1 In Glioblastoma

Research background:Glioma is the most common brain tumor,and glioblastoma(GBM),as the most malignant glioma,has the characteristics of strong aggressiveness,high recurrence rate,and high mortality rate.The current various treatment methods can not achieve better curative effect.Due to the invasiveness,gradual development of tumors,and the inability to cure these tumors by surgery or radiation therapy,current treatments are aimed at slowing the progression of the disease and prolonging survival.Searching for putative new molecular targets for GBM is an active area of research.Studies have shown that adjusting iron metabolism to regulate tumor growth is a promising direction for cancer treatment,because tumor cells have an increased demand for iron and regulate SLC40A1,ferritin receptor(TfR1),ferritin,ferritin,and hepcidin in tumors.Expression changes the balance of iron intake,storage and output in tumor cells,thereby restricting or supporting the growth of iron-dependent malignant tumor cells.SLC40A1 is currently the only member of the SLC40 transporter family,and is currently the only transfer protein found to promote the transfer of iron from the cell to the outside of the cell.Studies have shown that the expression of the iron export gene SLC40A1 in tumor cells is increased,which can inhibit hepatocellular carcinoma,breast cancer,Prostate cancer growth.However,there is no relevant literature report on the expression and role of SLC40A1 in GBM patients.Research purpose:To analyze the expression level and clinical significance of SLC40A1 in GBM,and to provide a basis for clinical diagnosis and treatment and diagnosis.Research methods:①In this study,the Oncomine database was used to analyze the expression of SLC40A1 in GBM tissues;②The GEPIA database was used to analyze the expression of SLC40A1 in GBM and the correlation of prognosis.And make a box comparison of its Oncomine data set.③Use the UALCAN database to analyze the relationship between SLC40A1 and clinical data(such as gender,age,etc.).④Use STRING database to analyze SLC40A1 related genes,and perform GO interpretation and KEEG pathway enrichment analysis.⑤Select GBM specimens from our hospital to complete the immunohistochemical determination,and judge the expression of SLC40A1 in the tissues according to immunohistochemical staining.⑥Collect relevant case data and analyze the prognostic effects of SLC40A1 on GBM under the influence of different genders and ages,and follow up the overall survival time of GBM patients,and use the R software to use the data to improve the Kaplan-Meyer survival curve analysis after one year surgery.The results are combined with the database Comparison of results.Result:1.Exploring the expression of SLC40A1 in GBM in the Oncomine database,GEPIA database and UALCAN database,and found that the expression of SLC40A1 in GBM tumor tissue was significantly higher than that of normal brain tissue.Further use of immunohistochemistry to analyze the expression of SLC40A1 protein in 55 cases of GBM tissue in our hospital and 10 cases of control group brain tissue.Compared with the brain tissue of the control group,the expression of SLC40A1 in GBM tissue was significantly higher(P<0.05).2.In the UALCAN database,there was no statistical significance between the age,gender and methylation level of patients and the expression of SLC40A1(P>0.05).According to the expression of SLC40A1,55 GBM patients in our hospital were divided into SLC40A1 high expression group(comprehensive score≥4 points)and low expression group(<4 points).Statistical analysis showed that the expression of SLC40A1 was not statistically significant with the patient’s age,gender,tumor size,and tumor location(P>0.05).The data analysis in our hospital was consistent with the database results.3.The analysis of the relationship between the expression level of SLC40A1 in GBM and the prognosis of patients based on database data in this study showed that SLC40A1 mRNA expression is related to the overall survival rate of patients.The higher the expression of SLC40A1,the higher the overall survival rate of patients(Logrank P=0.035<0.005).We further followed up the overall survival time of 52 GBM patients(3 cases excluded)in our hospital by telephone,and perfected the survival analysis to indicate that the higher the expression of SLC40A1,the higher the overall survival rate of patients(P=0.005<0.05),further confirming that SLC40A1 is in GBM plays an important role.Conclusion:This study shows that SLC40A1 is highly expressed in GBM tissues,and survival analysis shows that the higher the expression of SLC40A1 in GBM,the higher the survival rate,indicating that SLC40A1 is a protective factor for GBM,which can provide a targeted basis for clinical diagnosis and treatment of GBM.The mechanism may be related to reducing the iron content in tumor cells,thereby inhibiting tumor growth.